Kyverna Therapeutics, Inc. cash flow to debt ratio of -529.46% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Kyverna Therapeutics, Inc.'s free cash flow has decreased 32.00% from $-116.45M last year to $-153.72M, signaling decreasing performance

Kyverna Therapeutics, Inc.'s debt to equity ratio is 0.17, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Kyverna Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.03 last year to 0.17 today, signaling weakened financials

Kyverna Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Kyverna Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Kyverna Therapeutics, Inc. has insufficient data to evaluate this check.

Kyverna Therapeutics, Inc.'s short-term assets of $282.95M exceed its short-term liabilities of $36.49M

Kyverna Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Kyverna Therapeutics, Inc.'s return on equity of -81.87%, is lower than 15.00%, indicating bad performance

Kyverna Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Kyverna Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Kyverna Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Kyverna Therapeutics, Inc. has negative free cash flow, indicating cash burn

Kyverna Therapeutics, Inc.'s yearly earnings has decreased 26.54% since last year from $-127.48M to $-161.31M, signaling decreasing performance

Kyverna Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -71.42% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Kyverna Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Kyverna Therapeutics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Kyverna Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Kyverna Therapeutics, Inc. has insufficient data to evaluate this check.

Kyverna Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kyverna Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Kyverna Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Kyverna Therapeutics, Inc. has insufficient data to evaluate this check.

Kyverna Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kyverna Therapeutics, Inc. has a price-to-book ratio of 2.61x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Kyverna Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue